Do analysts recommend WHWK or EXOZ?

Whitehawk Therapeutics presently has a consensus target price of $8.33, indicating a potential upside of 136.74%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Whitehawk Therapeutics is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Whitehawk Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 eXoZymes 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is WHWK or EXOZ more profitable?

Whitehawk Therapeutics' return on equity of -53.89% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets Whitehawk Therapeutics N/A -53.89% -49.97% eXoZymes N/A -292.15% -158.66%

Does the media favor WHWK or EXOZ?

In the previous week, Whitehawk Therapeutics and Whitehawk Therapeutics both had 2 articles in the media. eXoZymes' average media sentiment score of 1.03 beat Whitehawk Therapeutics' score of 0.71 indicating that eXoZymes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive eXoZymes 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate TRDA or EXOZ?

Entrada Therapeutics currently has a consensus target price of $17.75, suggesting a potential upside of 213.05%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Entrada Therapeutics is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entrada Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 eXoZymes 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer TRDA or EXOZ?

In the previous week, Entrada Therapeutics and Entrada Therapeutics both had 2 articles in the media. eXoZymes' average media sentiment score of 1.03 beat Entrada Therapeutics' score of 0.15 indicating that eXoZymes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral eXoZymes 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ELDN or EXOZ?

Eledon Pharmaceuticals presently has a consensus price target of $10.00, suggesting a potential upside of 303.23%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Eledon Pharmaceuticals is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eledon Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 eXoZymes 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is ELDN or EXOZ more profitable?

Eledon Pharmaceuticals' return on equity of -149.63% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -149.63% -50.84% eXoZymes N/A -292.15% -158.66%

Does the media refer more to ELDN or EXOZ?

In the previous week, Eledon Pharmaceuticals and Eledon Pharmaceuticals both had 2 articles in the media. eXoZymes' average media sentiment score of 1.03 beat Eledon Pharmaceuticals' score of 0.91 indicating that eXoZymes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive eXoZymes 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ALEC or EXOZ?

Alector currently has a consensus target price of $3.40, suggesting a potential upside of 63.46%. Given Alector's stronger consensus rating and higher probable upside, equities research analysts clearly believe Alector is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alector 2 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.11 eXoZymes 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better valuation and earnings, ALEC or EXOZ?

eXoZymes has lower revenue, but higher earnings than Alector. eXoZymes is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alector $21.05M 11.03 -$142.93M -$1.10 N/A eXoZymes $70K 697.50 -$9.16M -$1.19 N/A

Is ALEC or EXOZ more profitable?

eXoZymes has a net margin of 0.00% compared to Alector's net margin of -850.13%. eXoZymes' return on equity of -292.15% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets Alector -850.13% -531.03% -44.00% eXoZymes N/A -292.15% -158.66%

Does the media refer more to ALEC or EXOZ?

In the previous week, Alector had 19 more articles in the media than eXoZymes. MarketBeat recorded 21 mentions for Alector and 2 mentions for eXoZymes. eXoZymes' average media sentiment score of 1.03 beat Alector's score of 0.57 indicating that eXoZymes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 2 Very Positive mention(s) 8 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive eXoZymes 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer EXOZ or ADAG?

Adagene has a consensus price target of $8.67, indicating a potential upside of 214.01%. Given Adagene's stronger consensus rating and higher possible upside, analysts plainly believe Adagene is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Adagene 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has stronger earnings & valuation, EXOZ or ADAG?

eXoZymes has higher earnings, but lower revenue than Adagene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio eXoZymes $70K 697.50 -$9.16M -$1.19 N/A Adagene $7.67M 23.77 -$17.61M N/A N/A

Is EXOZ or ADAG more profitable?

Adagene's return on equity of 0.00% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -292.15% -158.66% Adagene N/A N/A N/A

Does the media prefer EXOZ or ADAG?

In the previous week, Adagene had 2 more articles in the media than eXoZymes. MarketBeat recorded 4 mentions for Adagene and 2 mentions for eXoZymes. Adagene's average media sentiment score of 1.05 beat eXoZymes' score of 1.03 indicating that Adagene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eXoZymes 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adagene 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

eXoZymes (EXOZ) Competitors

$5.33 +0.06 (+1.14%)

As of 10/9/2026 04:00 PM Eastern

Compare

EXOZ vs. WHWK, TRDA, ELDN, ALEC, and ADAG

Should you buy eXoZymes stock or one of its competitors? eXoZymes's main competitors and comparable companies include Whitehawk Therapeutics (WHWK), Entrada Therapeutics (TRDA), Eledon Pharmaceuticals (ELDN), Alector (ALEC), and Adagene (ADAG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does eXoZymes compare to Whitehawk Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Whitehawk Therapeutics' return on equity of -53.89% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-53.89%	-49.97%
eXoZymes	N/A	-292.15%	-158.66%

52.1% of Whitehawk Therapeutics shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by insiders. Comparatively, 58.0% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Whitehawk Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, eXoZymes has a beta of 3.19, suggesting that its stock price is 219% more volatile than the broader market.

Whitehawk Therapeutics presently has a consensus target price of $8.33, indicating a potential upside of 136.74%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Whitehawk Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
eXoZymes	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

eXoZymes has lower revenue, but higher earnings than Whitehawk Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	28.11	-$20.60M	-$1.12	N/A
eXoZymes	$70K	697.50	-$9.16M	-$1.19	N/A

In the previous week, Whitehawk Therapeutics and Whitehawk Therapeutics both had 2 articles in the media. eXoZymes' average media sentiment score of 1.03 beat Whitehawk Therapeutics' score of 0.71 indicating that eXoZymes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
eXoZymes	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Whitehawk Therapeutics beats eXoZymes on 9 of the 14 factors compared between the two stocks.

How does eXoZymes compare to Entrada Therapeutics?

Entrada Therapeutics (NASDAQ:TRDA) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

86.4% of Entrada Therapeutics shares are held by institutional investors. 9.5% of Entrada Therapeutics shares are held by insiders. Comparatively, 58.0% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Entrada Therapeutics and Entrada Therapeutics both had 2 articles in the media. eXoZymes' average media sentiment score of 1.03 beat Entrada Therapeutics' score of 0.15 indicating that eXoZymes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entrada Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
eXoZymes	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Entrada Therapeutics currently has a consensus target price of $17.75, suggesting a potential upside of 213.05%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Entrada Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
eXoZymes	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

eXoZymes has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -3,537.73%. Entrada Therapeutics' return on equity of -57.61% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%
eXoZymes	N/A	-292.15%	-158.66%

eXoZymes has lower revenue, but higher earnings than Entrada Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	8.69	-$143.75M	-$3.96	N/A
eXoZymes	$70K	697.50	-$9.16M	-$1.19	N/A

Entrada Therapeutics has a beta of -0.24, suggesting that its stock price is 124% less volatile than the broader market. Comparatively, eXoZymes has a beta of 3.19, suggesting that its stock price is 219% more volatile than the broader market.

Summary

Entrada Therapeutics beats eXoZymes on 8 of the 15 factors compared between the two stocks.

How does eXoZymes compare to Eledon Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

In the previous week, Eledon Pharmaceuticals and Eledon Pharmaceuticals both had 2 articles in the media. eXoZymes' average media sentiment score of 1.03 beat Eledon Pharmaceuticals' score of 0.91 indicating that eXoZymes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
eXoZymes	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eledon Pharmaceuticals' return on equity of -149.63% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%
eXoZymes	N/A	-292.15%	-158.66%

eXoZymes has higher revenue and earnings than Eledon Pharmaceuticals. eXoZymes is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A
eXoZymes	$70K	697.50	-$9.16M	-$1.19	N/A

Eledon Pharmaceuticals presently has a consensus price target of $10.00, suggesting a potential upside of 303.23%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Eledon Pharmaceuticals is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
eXoZymes	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 58.0% of eXoZymes shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Eledon Pharmaceuticals has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, eXoZymes has a beta of 3.19, suggesting that its stock price is 219% more volatile than the broader market.

Summary

Eledon Pharmaceuticals beats eXoZymes on 8 of the 13 factors compared between the two stocks.

How does eXoZymes compare to Alector?

Alector (NASDAQ:ALEC) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

In the previous week, Alector had 19 more articles in the media than eXoZymes. MarketBeat recorded 21 mentions for Alector and 2 mentions for eXoZymes. eXoZymes' average media sentiment score of 1.03 beat Alector's score of 0.57 indicating that eXoZymes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	2 Very Positive mention(s)	8 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
eXoZymes	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

eXoZymes has a net margin of 0.00% compared to Alector's net margin of -850.13%. eXoZymes' return on equity of -292.15% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-850.13%	-531.03%	-44.00%
eXoZymes	N/A	-292.15%	-158.66%

Alector currently has a consensus target price of $3.40, suggesting a potential upside of 63.46%. Given Alector's stronger consensus rating and higher probable upside, equities research analysts clearly believe Alector is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11
eXoZymes	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

eXoZymes has lower revenue, but higher earnings than Alector. eXoZymes is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	11.03	-$142.93M	-$1.10	N/A
eXoZymes	$70K	697.50	-$9.16M	-$1.19	N/A

Alector has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, eXoZymes has a beta of 3.19, meaning that its stock price is 219% more volatile than the broader market.

85.8% of Alector shares are owned by institutional investors. 8.3% of Alector shares are owned by insiders. Comparatively, 58.0% of eXoZymes shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Alector beats eXoZymes on 9 of the 16 factors compared between the two stocks.

How does eXoZymes compare to Adagene?

eXoZymes (NASDAQ:EXOZ) and Adagene (NASDAQ:ADAG) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

Adagene has a consensus price target of $8.67, indicating a potential upside of 214.01%. Given Adagene's stronger consensus rating and higher possible upside, analysts plainly believe Adagene is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Adagene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Adagene had 2 more articles in the media than eXoZymes. MarketBeat recorded 4 mentions for Adagene and 2 mentions for eXoZymes. Adagene's average media sentiment score of 1.05 beat eXoZymes' score of 1.03 indicating that Adagene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adagene	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

9.5% of Adagene shares are held by institutional investors. 58.0% of eXoZymes shares are held by company insiders. Comparatively, 21.2% of Adagene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Adagene's return on equity of 0.00% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-292.15%	-158.66%
Adagene	N/A	N/A	N/A

eXoZymes has a beta of 3.19, meaning that its share price is 219% more volatile than the broader market. Comparatively, Adagene has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

eXoZymes has higher earnings, but lower revenue than Adagene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	697.50	-$9.16M	-$1.19	N/A
Adagene	$7.67M	23.77	-$17.61M	N/A	N/A

Summary

Adagene beats eXoZymes on 10 of the 14 factors compared between the two stocks.

Get eXoZymes News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXOZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EXOZ vs. The Competition

Export

Metric	eXoZymes	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$48.85M	$3.93B	$7.25B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	-4.41	13.55	275.01	26.14
Price / Sales	697.50	1,209.42	582.85	87.88
Price / Cash	N/A	119.49	76.96	53.71
Price / Book	13.13	17.17	11.22	6.33
Net Income	-$9.16M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-14.08%	-1.34%	-0.89%	-1.40%
1 Month Performance	-20.45%	-8.04%	-4.02%	-3.35%
1 Year Performance	-59.46%	14.18%	7.13%	1.49%

eXoZymes Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EXOZ eXoZymes	2.0312 of 5 stars	$5.25 -0.4%	N/A	-59.5%	$48.85M	$70K	N/A	32	News Coverage Positive News
WHWK Whitehawk Therapeutics	2.5181 of 5 stars	$3.70 -1.6%	$8.33 +125.2%	+74.3%	$210.93M	$7.14M	N/A	23
TRDA Entrada Therapeutics	2.5118 of 5 stars	$5.38 -5.3%	$17.75 +229.9%	-6.9%	$209.48M	$25.42M	N/A	152	News Coverage
ELDN Eledon Pharmaceuticals	2.1157 of 5 stars	$2.49 +2.5%	$10.00 +301.6%	-9.5%	$202.34M	N/A	N/A	33	Gap Up
ALEC Alector	2.0625 of 5 stars	$1.81 -2.7%	$3.63 +100.3%	-31.1%	$202.10M	$21.05M	N/A	103	Analyst Forecast Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EXOZ) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

eXoZymes (EXOZ) Competitors

EXOZ vs. WHWK, TRDA, ELDN, ALEC, and ADAG

How does eXoZymes compare to Whitehawk Therapeutics?

Summary

How does eXoZymes compare to Entrada Therapeutics?

Summary

How does eXoZymes compare to Eledon Pharmaceuticals?

Summary

How does eXoZymes compare to Alector?

Summary

How does eXoZymes compare to Adagene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXOZ vs. The Competition

eXoZymes Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

eXoZymes (EXOZ) Competitors

EXOZ vs. WHWK, TRDA, ELDN, ALEC, and ADAG

How does eXoZymes compare to Whitehawk Therapeutics?

Is WHWK or EXOZ more profitable?

Do institutionals & insiders believe in WHWK or EXOZ?

Which has more risk and volatility, WHWK or EXOZ?

Do analysts recommend WHWK or EXOZ?

Which has better valuation & earnings, WHWK or EXOZ?

Does the media favor WHWK or EXOZ?

Summary

How does eXoZymes compare to Entrada Therapeutics?

Do institutionals and insiders hold more shares of TRDA or EXOZ?

Does the media prefer TRDA or EXOZ?

Do analysts rate TRDA or EXOZ?

Is TRDA or EXOZ more profitable?

Which has stronger valuation and earnings, TRDA or EXOZ?

Which has more volatility & risk, TRDA or EXOZ?

Summary

How does eXoZymes compare to Eledon Pharmaceuticals?

Does the media refer more to ELDN or EXOZ?

Is ELDN or EXOZ more profitable?

Which has stronger earnings and valuation, ELDN or EXOZ?

Do analysts prefer ELDN or EXOZ?

Do institutionals & insiders hold more shares of ELDN or EXOZ?

Which has more volatility & risk, ELDN or EXOZ?

Summary

How does eXoZymes compare to Alector?

Does the media refer more to ALEC or EXOZ?

Is ALEC or EXOZ more profitable?

Do analysts prefer ALEC or EXOZ?

Which has better valuation and earnings, ALEC or EXOZ?

Which has more risk and volatility, ALEC or EXOZ?

Do institutionals and insiders hold more shares of ALEC or EXOZ?

Summary

How does eXoZymes compare to Adagene?

Do analysts prefer EXOZ or ADAG?

Does the media prefer EXOZ or ADAG?

Do insiders & institutionals have more ownership in EXOZ or ADAG?

Is EXOZ or ADAG more profitable?

Which has more risk and volatility, EXOZ or ADAG?

Which has stronger earnings & valuation, EXOZ or ADAG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXOZ vs. The Competition

eXoZymes Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools